Peplin raises $3.5m, plans to broaden pipeline
Monday, 02 June, 2003
Queensland-based Peplin Biotech has raised $AUD3.5 million before expenses through the placement of five million shares at $AUD0.70 to domestic and international institutional investors.
Company chair Cherrell Hirst said that while the milestone payments from collaborator Allergan would underpin Peplin's cash flow, the additional funding would open up the opportunity to broaden and accelerate the company's drug pipeline and technology platform.
CEO and managing director Garry Redlich said the placement met the median expectations of the company.
"We were always very open about what the market would do... we didn't want massive dilutions," he said. "We're very pleased to have an increasing valuation."
Wilson HTM and ABN AMRO Morgans acted as joint placement agents for the shares. At the time of writing Peplin's share price (ASX: PEP) was trading at $AUD0.75.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
